The Lead Episode 38: A Discussion of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation-The Lead Episode 38 Speaker Information

The Lead Episode 38 Speaker Information

Pdf Summary

This discussion focuses on the article "Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation" published in the New England Journal of Medicine. The hosts for this discussion are Janice Y. Chyou, MD, FHRS from the Icahn School of Medicine at Mount Sinai, and the contributors are Mintu P Turakhia, MD, MS from iRhythm Technologies and Stanford University, and Jonathan P. Piccini, Sr., MD, MHS, FHRS from Duke University Medical Center.<br /><br />The disclosures for the contributors include various Honoraria/Speaking/Consulting and research affiliations with pharmaceutical companies, medical associations, and technology companies.<br /><br />The article being discussed explores the use of the anticoagulant apixaban for stroke prevention in individuals with subclinical atrial fibrillation. Subclinical atrial fibrillation refers to episodes of atrial fibrillation that are not clinically apparent or symptomatic.<br /><br />The discussion aims to analyze the findings of the study and discuss the implications for stroke prevention in patients with subclinical atrial fibrillation. The contributors discuss the benefits and potential risks of using apixaban for this purpose.<br /><br />Overall, this discussion provides a platform for experts to exchange ideas and perspectives on the topic of apixaban for stroke prevention in subclinical atrial fibrillation. By examining the findings of the article and considering their own experiences and insights, the contributors aim to provide a comprehensive understanding of the potential role of apixaban in this patient population.

Keywords

Apixaban

Stroke Prevention

Subclinical Atrial Fibrillation

New England Journal of Medicine

Janice Y. Chyou

Mintu P Turakhia

Jonathan P. Piccini Sr.

Anticoagulant

Findings

Implications